Advertisement
Canada markets closed

  • S&P/TSX

    24,471.17
    +168.87 (+0.69%)
     

  • S&P 500

    5,815.03
    +34.98 (+0.61%)
     

  • DOW

    42,863.86
    +409.76 (+0.97%)
     

  • CAD/USD

    0.7256
    -0.0013 (-0.18%)
     

  • CRUDE OIL

    74.44
    -1.12 (-1.48%)
     

  • Bitcoin CAD

    86,467.78
    -342.69 (-0.39%)
     

  • XRP CAD

    0.73
    -0.01 (-1.12%)
     

  • GOLD FUTURES

    2,663.60
    -12.70 (-0.47%)
     

  • RUSSELL 2000

    2,234.41
    +45.99 (+2.10%)
     

  • 10-Yr Bond

    4.0730
    -0.0230 (-0.56%)
     

  • NASDAQ futures

    20,409.25
    -40.75 (-0.20%)
     

  • VOLATILITY

    20.46
    -0.47 (-2.25%)
     

  • FTSE

    8,253.65
    +15.92 (+0.19%)
     

  • NIKKEI 225

    39,605.80
    +224.90 (+0.57%)
     

  • CAD/EUR

    0.6641
    -0.0001 (-0.02%)
     

Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·2 min read

For the quarter ended December 2023, Guardant Health (GH) reported revenue of $155.05 million, up 22.2% over the same period last year. EPS came in at -$1.58, compared to -$1.36 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $151.71 million, representing a surprise of +2.20%. The company delivered an EPS surprise of -69.89%, with the consensus EPS estimate being -$0.93.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Guardant Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Total tests performed (clinical & biopharmaceutical customers): 55,900 compared to the 54,975 average estimate based on three analysts.

  • Revenue- Development services and other: $12.87 million compared to the $9.79 million average estimate based on six analysts. The reported number represents a change of -1.8% year over year.

  • Revenue- Precision oncology testing: $142.19 million versus the six-analyst average estimate of $136.31 million. The reported number represents a year-over-year change of +25%.

View all Key Company Metrics for Guardant Health here>>>

Shares of Guardant Health have returned +0.5% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Guardant Health, Inc. (GH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research